SCHEMBL1689746

SCHEMBL1689746

O=C(c1ccnc(Cl)c1)N1CC2(CCN(CC=Cc3ccc(Cl)cc3)CC2)c2cc(I)ccc21

nearest known ligand 0.84

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
EBP Q15125 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
NOTUM Q6P988 1/20 0.36
PROKR1 Q8TCW9 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
DHCR7 Q9UBM7 1/20 0.35
LMNA P02545 3/20 0.35
TACR3 P29371 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
POLB P06746 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1689743 1.00 SMN1; SMN2 (0.38) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1
SCHEMBL13968936 0.94 NOTUM (0.42) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1
SCHEMBL895335 0.91 SMN1; SMN2 (0.38) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1
SCHEMBL29368845 0.91 SMN1; SMN2 (0.38) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1
SCHEMBL12459610 0.91 SMN1; SMN2 (0.38) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1
SCHEMBL13563959 0.91 NOTUM (0.40) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1
SCHEMBL895333 0.91 SMN1; SMN2 (0.38) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1
SCHEMBL13563961 0.90 NOTUM (0.39) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1
SCHEMBL12459564 0.90 MEN1 (0.41) SMN1; SMN2EBPSIGMAR1NOTUMLMNA
SCHEMBL12459579 0.89 NOTUM (0.40) SMN1; SMN2EBPSIGMAR1NOTUMPROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515969-B2 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA LTD (GB) 2017-10-11 EP disclosed
US-9686990-B2 Spiroindolinepiperidine derivatives SYNGENTA PARTICIPATIONS AG (CH) 2017-06-27 US disclosed
US-20160007608-A1 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA LIMITED (GB) 2016-01-14 US disclosed
US-9174987-B2 Spiroindolinepiperidine derivatives SYNGENTA LIMITED (DE) 2015-11-03 US disclosed
EP-1880996-B1 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA LTD (GB) 2014-12-24 EP disclosed
US-20120010220-A1 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA CROP PROTECTION LLC (US) 2012-01-12 US disclosed
EP-1515969-B1 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA LTD (GB) 2010-08-25 EP disclosed
EP-1880996-A1 Spiroindolinepiperidine derivatives Syngenta Limited (GB) 2008-01-23 EP disclosed
US-20060106045-A1 Spiroindolinepiperidine derivatives SYNGENTA PARTICIPATIONS AG (CH) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010220-A1 SPIROINDOLINEPIPERIDINE DERIVATIVES RECQL, OPRD1, SKP1 SMN1; SMN2 935/4885EBP 1155/4885SIGMAR1 85/4885
US-20060106045-A1 Spiroindolinepiperidine derivatives RECQL, OPRD1, NCAPD3 SMN1; SMN2 1132/4885EBP 987/4885SIGMAR1 143/4885
US-20160007608-A1 SPIROINDOLINEPIPERIDINE DERIVATIVES RECQL, OPRD1, SKP1 SMN1; SMN2 935/4885EBP 1155/4885SIGMAR1 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.